In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
New Jersey, USA,-
A new report titled (Baby Formula Market) from Market Research Intellect sheds light on industry dynamics and current and future trends...